Thursday, March 7, 2013

Heart Failure Mortality Linked to Glucose Levels - Fiore

Heart Failure Mortality Linked to Glucose Levels

By Kristina Fiore, Staff Writer, MedPage Today
Published: January 17, 2013
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner
Serum glucose measured at the time of hospital admission predicted 30-day mortality in acute heart failure patients, researchers reported.

“Our results are consistent with basic and clinical science data linking an elevated blood glucose level with myocardial injury, impaired myocardial performance, arrhythmia, and risk of ventricular remodeling,” they wrote.

Elevated glucose has also been associated with worse outcomes for patients with stroke and other critical illnesses, the researchers said, but its short-term prognostic impact in acute heart failure isn’t known.

Mebazaa and colleagues analyzed data from a multi-national cohort of 6,212 acute heart failure patients who had a mean age of 72, and 41% of whom had a previous diagnosis of diabetes.

The mean blood glucose concentration on arrival at the hospital was 7.5 mmol/L (135 mg/dL), and after 30 days, 10% of the patients had died.

Mebazaa and colleagues found that patients who died had a significantly higher median blood glucose concentration at admission compared with survivors ...

The risk between blood sugar levels and 30-day mortality was consistent across all subgroups of patients, the researchers reported,

They also emphasized that the relationship between blood sugar and death was seen in patients both with and without a previous diagnosis of diabetes.

In sensitivity analyses, adjusting for factors such as left ventricular ejection fraction (LVEF) and plasma natriuretic peptides, as well as excluding patients from the largest cohort, didn’t significantly alter any of the findings.
The researchers said it was not clear whether elevated blood sugar in acute heart failure is “a marker for risk or a mediator of adverse outcomes” — but since serum glucose is “widely measured, easily interpreted, and inexpensive to measure,” using it in risk assessment is “worthy of consideration.”
The study was limited by a lack of data on glycated hemoglobin (HbA1c) at admission and by the absence of serial measurements of glucose during the hospital stay.

Further work is needed to better understand the pathophysiology and complete trajectory of hyperglycemia in acute heart failure, they concluded.
Read the complete article here.

Download Complimentary Source PDF

No comments:

Post a Comment

I appreciate appropriate comments but reserve the right to publish those with credible, verifiable, significant information to contribute to the topic at hand. I will not post comments with commercial content nor those containing personal attacks. Thank You.